Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NextCell Pharma ABOSTO:NXTCL -0.20%42 Days Payable is 142.74 as of Dec. 2025, which is 264% above its 10-year median of 39.18. GuruFocus rates OSTO:NXTCL with a GF Score™ of 42/100 and a GF Value™ of kr0.90 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 702 Biotechnology companies, NextCell Pharma AB ranks better than 54.13% on this metric.
The historical rank and industry rank for NextCell Pharma AB's Days Payable or its related term are showing as below:
OSTO:NXTCL'
s Days Payable Range Over the Past 10 Years
Min: 17.41 Med: 39.18 Max: 291.31
Current: 130.14
During the past 11 years, NextCell Pharma AB's highest Days Payable was 291.31. The lowest was 17.41. And the median was 39.18.
OSTO:NXTCL's Days Payable is ranked better than 54.13% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs OSTO:NXTCL: 130.14
NextCell Pharma AB's Days Payable
declined
from Nov. 2024 (151.05) to Dec. 2025 (142.74).
It may suggest that NextCell Pharma ABaccelerated paying its suppliers.
NextCell Pharma AB Days Payable Related Terms
NextCell Pharma AB Days Payable Historical Data
* Premium members only.
The historical data trend for NextCell Pharma AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:NXTCL vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, NextCell Pharma AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCell Pharma AB Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's Days Payable distribution charts can be found below:
* The bar in red indicates where NextCell Pharma AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
NextCell Pharma AB's Days Payable for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NextCell Pharma AB (OSTO:NXTCL) has a Days Payable of 142.74 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on NextCell Pharma AB and its competitors. This is 264% above median its historical median of 39.18. Over the past decade, NextCell Pharma AB's Days Payable has ranged from 17.41 to 291.31. According to the industry distribution chart, NextCell Pharma AB ranks #322 out of 702 companies in the Biotechnology industry, placing it in the top 45.9%.
Is NextCell Pharma AB's Days Payable too high?
NextCell Pharma AB's current Days Payable of 142.74 is 264% above median its 10-year median of 39.18. Over the past 10 years, this metric has ranged from a low of 17.41 to a high of 291.31. The Biotechnology industry median Days Payable is 113.10. NextCell Pharma AB's value of 142.74 is 26.2% above this industry median. Based on the distribution chart, NextCell Pharma AB ranks #322 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, NextCell Pharma AB has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, NextCell Pharma AB ranks #322 out of 702 companies for Days Payable. This puts NextCell Pharma AB in the upper half of its industry. The industry median Days Payable is 113.10. NextCell Pharma AB's value of 142.74 is 26.2% above this benchmark. Historically, NextCell Pharma AB's own Days Payable has ranged from 17.41 to 291.31 over the past decade. While the company's 10-year median is 39.18 vs. the industry median of 113.10, NextCell Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NextCell Pharma AB's current Days Payable of 142.74 is 26.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on NextCell Pharma AB and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NextCell Pharma AB's current Days Payable is 142.74, which is 264% above median its own 10-year median of 39.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (OSTO:NXTCL) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.90, compared to a current price of kr1.01 — trading 12.2% above its estimated fair value. The current Days Payable is 142.74, which is 264% above median its 10-year median of 39.18 and 26.2% above the Biotechnology industry median of 113.10. NextCell Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For NextCell Pharma AB (OSTO:NXTCL), the current Days Payable is 142.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NextCell Pharma AB (OSTO:NXTCL) Overvalued in 2026?
Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued.
The current stock price of kr1.01 is trading 12.2% above its estimated GF Value™ of kr0.90.
GuruFocus considers NextCell Pharma AB to be Modestly Overvalued.
Key valuation signals for OSTO:NXTCL:
Days Payable: 142.74 (264% above median its 10-year median of 39.18)
GF Value™: kr0.90 vs. price of kr1.01 (12.2% above fair value)
Industry Position: 26.2% above the Biotechnology median (#322 of 702)
No single metric tells the full story. See the OSTO:NXTCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
42GF Score
Get the complete analysis for OSTO:NXTCL
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NXTCL has been successfully added to your 
